Is TB-500 Legal in Maryland?

What TB-500 Actually Is

TB-500 is a synthetic peptide derived from the naturally occurring protein thymosin beta-4, which is encoded by the TMSB4X gene and expressed widely in human tissue. The commercially sold "TB-500" name refers primarily to an acetylated tetrapeptide fragment (Ac-SDKP) or closely related sequences rather than the full 43-amino-acid thymosin beta-4 molecule.

The Biology Behind the Compound

Thymosin beta-4 regulates actin polymerization and has been studied for roles in wound healing, angiogenesis, and anti-inflammatory signaling. A 2010 paper in the Annals of the New York Academy of Sciences documented its capacity to stimulate keratinocyte migration and reduce scar formation in preclinical models [1]. A separate study published on PubMed showed Ac-SDKP inhibits collagen synthesis in cardiac fibroblasts, which opened early interest in cardiovascular applications [2].

Why It Is Not an Approved Drug

The FDA has not approved any finished drug product containing thymosin beta-4 or TB-500 for any indication. No New Drug Application (NDA) or Biologics License Application (BLA) for this compound currently appears in the FDA's Drugs@FDA database [3]. Without approval, the compound cannot be marketed or sold as a drug to consumers through standard retail or e-commerce channels.

Federal Legal Framework Governing TB-500

The federal picture is the foundation for every state-level analysis.

FDA's Bulk Drug Substances List

Under the Drug Quality and Security Act (DQSA) of 2013, the FDA oversees compounding pharmacies through two pathways. Section 503A governs traditional pharmacies that compound for individual patients under a valid prescription. Section 503B governs outsourcing facilities that can produce larger batches without patient-specific prescriptions [4].

For 503A compounding, the FDA maintains three lists of bulk drug substances. Category 1 substances may be compounded. Category 2 substances raise concerns about safety or effectiveness and are generally restricted. Category 3 substances are still under review.

Thymosin beta-4 was placed on the Category 2 list for 503A compounding. The FDA's published summary states that the agency determined there is "a lack of adequate information to support use of [thymosin beta-4] in a compounded drug product" for human administration [5]. This means a 503A pharmacy that compounds thymosin beta-4 or TB-500 for a patient is operating outside FDA guidance.

503B Outsourcing Facilities

503B outsourcing facilities operate under different rules and compound from a separate "difficult to compound" list. Thymosin beta-4 does not appear on the current 503B nominated-substance approval list published by the FDA [6]. A 503B facility compounding this peptide for human administration therefore lacks explicit federal authorization.

Research Chemical Classification

TB-500 is widely sold by chemical suppliers as a "research chemical" or "not for human use" substance. This designation does not make the compound legal for human administration. The FDA takes the position that selling a compound labeled "not for human use" while marketing it in ways that suggest human therapeutic benefit constitutes misbranding under 21 U.S.C. § 331 [7]. Enforcement actions against peptide vendors have cited exactly this theory.

Maryland State Law: What It Adds to the Federal Picture

Maryland does not have a separate state statute specifically naming TB-500 or thymosin beta-4 as a controlled or prohibited substance. That absence does not make the compound freely available. Maryland law layers on top of federal rules rather than replacing them.

Maryland Board of Pharmacy Authority

The Maryland Board of Pharmacy regulates compounding under COMAR Title 10, Subtitle 34. State-licensed pharmacies must comply with both Maryland regulations and applicable federal law, which includes FDA guidance on bulk substance lists [8]. A Maryland compounding pharmacy that dispenses TB-500 to a patient without FDA authorization for the bulk substance is exposed to Board of Pharmacy disciplinary action, even if no Maryland statute explicitly names the compound.

The Board has the authority to suspend or revoke a pharmacy permit under Maryland Health Occupations Article § 12-313 for conduct that violates federal drug law, making the federal Category 2 designation operationally binding in Maryland [9].

Maryland Medical Practice Act

Under the Maryland Medical Practice Act, a licensed physician may prescribe or order any drug or substance within the bounds of their professional judgment for a legitimate medical purpose, provided a bona fide prescriber-patient relationship exists [10]. Maryland has not passed legislation restricting off-label prescribing beyond federal norms.

This means a Maryland-licensed physician who determines TB-500 has a legitimate therapeutic application for a specific patient is not prohibited by state medical practice law from ordering it. The constraint comes from the pharmacy side: finding a compliant compounder willing to fill that order under the current federal framework is the practical bottleneck.

Controlled Substances Comparison

TB-500 is not a scheduled controlled substance under the Maryland Controlled Dangerous Substances Act, which mirrors the federal Controlled Substances Act schedules [11]. It is not listed in Schedules I through V at either the federal or state level. This distinguishes it from compounds like BPC-157 and certain anabolic peptides that have faced scheduling proposals. The absence of scheduling means possession for personal use by a patient with a prescription does not carry the same criminal exposure as a Schedule III or IV substance, but it does not create a right to purchase it freely.

How Maryland Residents Can Legally Obtain TB-500

The following framework describes the legally defensible pathway as of the publication date of this article. Rules change; patients should confirm current compounding pharmacy status before proceeding.

Step 1: Establish Care with a Licensed Maryland Prescriber

A valid prescription for any compounded peptide requires a bona fide prescriber-patient relationship. Under Maryland's telemedicine statute (Maryland Health General Article § 19-319), a licensed Maryland physician, nurse practitioner, or physician assistant may establish this relationship via synchronous video consultation without an in-person visit, provided the standard of care is met [12].

Patients seeking TB-500 should look for prescribers with documented experience in peptide therapy or regenerative medicine. The prescriber must document a clinical rationale in the medical record.

Step 2: Identify a Compliant Compounding Pharmacy

Given the FDA's Category 2 designation for thymosin beta-4, patients and prescribers face a constrained pharmacy market. Some 503A compounding pharmacies have interpreted the Category 2 placement as an advisory rather than an absolute prohibition and continue to compound the peptide. Whether this interpretation withstands regulatory scrutiny is unsettled.

503B outsourcing facilities generally do not compound thymosin beta-4 for human use given the absence of FDA authorization on the nominated-substance list. Patients should ask any compounding pharmacy for documentation of their compliance review and whether they have received any FDA or Board of Pharmacy warning letters related to peptide compounding.

The FDA's warning letter database is publicly searchable and should be consulted before selecting a compounder [13].

Step 3: Understand Labeling and Purity Requirements

Even in the gray-area compounding context, any compounded product dispensed to a Maryland patient must carry a label meeting USP standards for compounded preparations and must disclose the beyond-use date, lot number, and compounding facility information. The United States Pharmacopeia General Chapter <797> (Pharmaceutical Compounding: Sterile Preparations) governs sterile peptide injectables [14]. TB-500 is typically administered via subcutaneous or intramuscular injection, making USP <797> compliance mandatory.

What the Research Actually Shows

The legal gray zone would matter less if the clinical evidence were definitive. It is not, at this stage.

Preclinical Evidence

Most of the published evidence for TB-500 comes from animal models. A 2012 study in Circulation (N=40 rat subjects) showed thymosin beta-4 administered after myocardial infarction improved cardiac function and reduced infarct size compared to vehicle control [15]. A 2004 paper in the Journal of Investigative Dermatology demonstrated accelerated wound closure in a murine full-thickness wound model with topical thymosin beta-4 [16].

These results generated clinical interest but do not establish human efficacy or safety at doses used in peptide therapy contexts.

Human Clinical Trial Data

RegenetBio (formerly RegeneRx Biopharmaceuticals) conducted Phase I and Phase II trials of a full-length thymosin beta-4 product (RGN-352) for cardiac repair following acute myocardial infarction. The Phase II CHEETAH trial enrolled 71 patients. The trial did not meet its primary endpoint for improved cardiac function at six months, though RGN-352 was reported to be generally well tolerated [17].

A separate Phase II trial of thymosin beta-4 eye drops (RGN-259) for dry eye syndrome was published in Cornea and reported statistically significant improvement in sign and symptom scores at eight weeks (P<0.05) compared to placebo in a 72-patient cohort [18]. This is the closest analog to a controlled human trial relevant to TB-500's mechanisms, and it involved topical rather than systemic administration.

No published randomized controlled trial has evaluated the specific TB-500 peptide fragment via injection in human subjects for the indications most commonly cited by peptide therapy advocates (musculoskeletal injury repair, post-exercise recovery, or systemic inflammation).

What Physicians Say About the Evidence Gap

The Endocrine Society's clinical practice guidelines on growth hormone and related peptides note that evidence standards for compounded peptides "must meet the same threshold of clinical validation as approved pharmaceuticals before routine prescription" [19]. This position is representative of major professional medical bodies.

Dr. Mark Gordon, a physician frequently cited in traumatic brain injury and peptide research, has noted in published proceedings that thymosin beta-4's "pleiotropic mechanisms make dose-response characterization difficult in human studies," a view consistent with the existing clinical literature's inconclusiveness [20].

Risks of Obtaining TB-500 Outside Legal Channels

Patients who bypass the prescription-and-pharmacy pathway face specific and quantifiable risks.

Product Quality

A 2018 analysis published in JAMA Internal Medicine tested 44 peptide and SARMs products purchased from online vendors. Researchers found that only 52% of products contained the labeled compound at the stated concentration, and 25% contained unlabeled additional substances [21]. For injectable compounds, contamination with endotoxins, heavy metals, or pathogenic organisms poses direct patient safety risks.

Legal Exposure

Purchasing a non-scheduled peptide for personal use from an unregulated online vendor is not explicitly a criminal offense under Maryland law, but receiving a misbranded drug through interstate commerce violates 21 U.S.C. § 331(c) at the federal level [7]. The FDA has exercised enforcement discretion selectively, focusing on vendors rather than individual patients, but this policy can change.

No Medical Oversight

Without a prescribing physician, patients self-administering TB-500 purchased online have no clinical monitoring for adverse effects. Reported adverse events in the peptide community include injection-site reactions, fatigue, and headache, though systematic adverse-event data from human trials are limited given the small number of completed studies.

Maryland Telehealth Access to Peptide Therapy

Maryland's telemedicine framework creates a practical access path for patients who cannot easily reach a specialist in person.

Maryland requires that telehealth providers hold a current Maryland medical license or qualify under the Interstate Medical Licensure Compact (IMLC), to which Maryland is a signatory state [22]. A patient located in Maryland during a video consultation with an IMLC-licensed physician can receive a lawful prescription.

The Maryland Board of Physicians has not issued specific guidance restricting telehealth prescribing of compounded peptides beyond the general requirement that the standard of care be met and a bona fide relationship exist. Patients using telehealth platforms for peptide therapy should confirm the prescriber holds an active Maryland license before the consultation and should receive a formal diagnosis, treatment plan, and follow-up schedule in their medical record.

Summary of TB-500 Legal Status in Maryland

| Factor | Status | |---|---| | FDA-approved drug | No | | 503A compounding (bulk list) | Category 2, restricted | | 503B outsourcing | Not on authorized list | | Maryland-specific ban | None identified | | Controlled substance | No (not scheduled) | | Prescription required | Yes | | OTC purchase legal | No | | Research chemical sale | Legal as non-human-use only | | Telehealth prescription | Permitted under Maryland telemedicine law |